Rational design of 9-vinyl-phenyl noscapine as potent tubulin binding anticancer agent and evaluation of the effects of its combination on Docetaxel.
9-vinyl-phenyl noscapine
anti-tumor activity
combination drug therapy
molecular docking
molecular dynamics simulations
noscapine
noscapinoids
tubulin binding affinity
Journal
Journal of biomolecular structure & dynamics
ISSN: 1538-0254
Titre abrégé: J Biomol Struct Dyn
Pays: England
ID NLM: 8404176
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
2
7
2020
medline:
25
2
2023
entrez:
2
7
2020
Statut:
ppublish
Résumé
Docetaxel (DOX) based combination therapy is a novel therapeutic strategy that attracts great interest in breast cancer treatment but its clinical utility got limited due to side effects. In contrast, noscapine, an antitussive drug showed antitumor activity against many cancers without any side effects that targets microtubules and attenuates its dynamic instability. In the quest for an increase in the anticancer activity of noscapine, we strategically designed a novel derivative, 9-vinyl phenyl noscapine (VPN), based on our
Identifiants
pubmed: 32608323
doi: 10.1080/07391102.2020.1785945
doi:
Substances chimiques
Antineoplastic Agents
0
Tubulin
0
Docetaxel
15H5577CQD
Noscapine
8V32U4AOQU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM